- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01514357
Nesiritide in Resistant Hypertension
Novel Peptides in Resistant Human Hypertension
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypertension remains a global burden in cardiovascular disease leading to stroke, myocardial infarction, and heart failure. Its myocardial complications result from increased mechanical load on the heart. Under physiological conditions of increased myocardial load and resulting myocardial stretch, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) synthesis and secretion occur contributing to maintenance of optimal cardiorenal and blood pressure homeostasis. However, studies indicate that in subjects with cardiovascular diseases the biological structure of these hormones may be altered, thus reducing their favorable protective activities. New studies indicate that early and moderate hypertension is associated with a derangement of the natriuretic peptide system which is characterized by the lack of activation of biologically active ANP and BNP, while severe hypertension is characterized by cardiac release of altered molecular forms of ANP and BNP that have reduced biological properties and/or enhanced degradation.
The broad objective of proposal is to advance the biology and therapeutics of the natriuretic peptides (NPs) with a special focus on the cardiac peptide BNP in human hypertension. The investigators' proposal is based upon the biological properties of BNP (i.e., natriuretic, renin-angiotensin-aldosterone suppressing, vasodilating, anti-fibrotic, anti-hypertrophic and positive lusitropic), its mechanistic role in human hypertension, and thus its potential as an innovative chronic protein therapeutic to enhance the treatment of patients with uncontrolled and or resistant hypertension. Importantly, BNP is an endocrine hormone normally produced by the human heart, and its use as therapeutic agent has been approved in USA for more than a decade and has been proven to be safe.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
Subjects with resistant hypertension as defined by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines, systolic blood pressure and/or diastolic blood pressure > 140/90 mm Hg. For patients with hypertension and diabetes or renal disease, blood pressure > 130/80 mm Hg despite treatment with diuretic, sympathetic depressant and vasodilators.
Medications may include a three drug regimen including:
- diuretic at therapeutic dose
- a second line agent such as sympatholytic (e.g. beta-blockade, central agent such as clonidine) or angiotensin converting enzyme inhibitor (ACEi) / angiotensin receptor blocker (ARB) or calcium channel blocker (CCB).
- third line agent including one of the above and/or direct vasodilator, such as hydralazine or minoxidil.
Exclusion criteria:
- Congestive Heart Failure (any New York Heart Association (NYHA) class)
- Ejection Fraction < 50%
- Known renal artery stenosis
- Myocardial infarction within 3 months of screening
- Unstable angina within 14 days of screening, or any evidence of myocardial ischemia
- Moderate to severe pulmonary hypertension
- Valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active myocarditis
- Sustained ventricular tachycardia or ventricular fibrillation within 14 days of screening
- Sustained Atrial Fibrillation
- Second or third degree atrioventricular (AV) block without a permanent cardiac pacemaker
- Cerebral vascular accident within 3 months of screening, or other evidence of significantly compromised central nervous system perfusion
- Total bilirubin of > 1.5 mg/dL or aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 1.5 times the upper limit of normal range
- Renal insufficiency assessed by calculated Glomerular Filtration Rate (GFR) < 30 ml/min (Cockcroft-Gault equation)
- Serum sodium of < 125 milliequivalent (mEq)/dL or > 160 mEq/dL
- Serum potassium of < 3.0 mEq/dL or > 5.5 mEq/dL
- Women taking hormonal contraceptives
- Pregnancy
- Body mass index (BMI) > 35
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Nesiritide (BNP)
Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days.
The initial starting dose was 5 micrograms/kg.
|
NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology.
Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Subjects will receive SQ placebo bid for seven consecutive days.
|
Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Systolic Blood Pressure (BP)
Time Frame: baseline, treatment day 1, treatment day 2
|
The change in BP with treatment over 7 days was assessed by the mean BP on admission, (treatment day 1) mean BP 23 hours after the first injection of BNP, and mean BP 23 hours after the second injection of BNP (treatment day 2).
Treatment day 2 was 7 days after admission.
|
baseline, treatment day 1, treatment day 2
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: John C Burnett, M.D., Mayo Clinic
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-001372
- UL1RR024150 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Recruiting
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Nesiritide (BNP)
-
Mayo ClinicNational Institutes of Health (NIH)Completed
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsCompletedLeft Ventricular Diastolic DysfunctionUnited States
-
Mayo ClinicScios, Inc.CompletedBNP (Nesiritide) vs. Placebo to Protect Kidney Function in Patients Undergoing Heart Bypass Surgery.Acute Kidney FailureUnited States
-
Horng ChenFlowMedica, Inc.TerminatedCardiorenal SyndromeUnited States
-
Mayo ClinicCompletedAcute Myocardial InfarctionUnited States
-
Horng ChenNational Heart, Lung, and Blood Institute (NHLBI); American Heart Association; National Center for Research Resources (NCRR) and other collaboratorsCompletedCongestive Heart Failure | CardiomyopathyUnited States
-
Oslo University HospitalUniversity of Oslo; University Hospital, AkershusRecruiting
-
Horng ChenNational Heart, Lung, and Blood Institute (NHLBI); National Center for Research...CompletedCongestive Heart FailureUnited States
-
Mayo ClinicNational Heart, Lung, and Blood Institute (NHLBI); National Center for Research...CompletedHeart Failure | Asymptomatic Systolic DysfunctionUnited States
-
VA Office of Research and DevelopmentTerminatedObesity | Metabolism | Cardiovascular Physiological PhenomenaUnited States